iSpecimen Inc. (NASDAQ:ISPC – Get Rating) saw a large growth in short interest in April. As of April 30th, there was short interest totalling 183,100 shares, a growth of 33.3% from the April 15th total of 137,400 shares. Currently, 3.4% of the company’s stock are sold short. Based on an average trading volume of 494,900 shares, the short-interest ratio is presently 0.4 days.
iSpecimen stock traded down $0.10 during midday trading on Wednesday, reaching $2.43. 1,946 shares of the company’s stock were exchanged, compared to its average volume of 399,036. iSpecimen has a 52 week low of $2.07 and a 52 week high of $28.98. The company has a current ratio of 14.73, a quick ratio of 14.73 and a debt-to-equity ratio of 0.12. The stock’s 50-day simple moving average is $3.66 and its 200 day simple moving average is $6.24.
Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in iSpecimen by 903.6% during the first quarter. BlackRock Inc. now owns 71,175 shares of the company’s stock worth $382,000 after acquiring an additional 64,083 shares during the last quarter. Teton Advisors Inc. acquired a new stake in iSpecimen during the first quarter worth approximately $215,000. Grimes & Company Inc. acquired a new stake in iSpecimen during the first quarter worth approximately $187,000. Millennium Management LLC acquired a new stake in iSpecimen during the third quarter worth approximately $162,000. Finally, Bleichroeder LP lifted its position in iSpecimen by 3.0% during the third quarter. Bleichroeder LP now owns 618,180 shares of the company’s stock worth $3,607,000 after acquiring an additional 17,889 shares during the last quarter. Institutional investors and hedge funds own 28.26% of the company’s stock.
iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.
- Get a free copy of the StockNews.com research report on iSpecimen (ISPC)
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
- Dynatrace: Fundamentals are Positive While Being Punished
- Now’s The Time To Buy Disney (NYSE: DIS)
- 3 Small Caps With Big Return Potential
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.